# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 03-13-2024 | 12-31-2023 | 10-K |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Indaptus Therapeutics (NASDAQ:INDP) with a Buy and maintains $...
Data demonstrates that Company's Decoy platform successfully induces or activates multiple immune celltypes involved in ant...
Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(1.83) per share which beat the analyst consensus estimate of...
• Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to...